|
|
|
Insider
Information: |
Topper James N |
Relationship: |
|
City: |
Seattle |
State: |
WA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
14 |
|
Direct
Shares |
20,705,444 |
|
Indirect Shares
|
36,606,767 |
|
|
Direct
Value |
$202,318,919 |
|
|
Indirect Value
|
$701,397,711 |
|
|
Total
Shares |
57,312,211 |
|
|
Total
Value |
$903,716,629 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
3
|
1
|
Stock
price went up :
|
0
|
1
|
Stock
price went down : |
3
|
0
|
|
|
|
Gain/Loss Ratio : |
-3.0
|
1.0
|
Percentage
Gain/Loss : |
-17.1%
|
0.3%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
La Jolla Pharmaceutical Co |
LJPC |
Director |
2005-12-14 |
0 |
2009-02-26 |
0 |
Premium* |
|
Amicus Therapeutics Inc |
FOLD |
Director, 10% Owner |
2007-06-05 |
0 |
2008-03-10 |
3,520,678 |
Premium* |
|
Portola Pharmaceuticals Inc |
PTLA |
Director |
2013-05-28 |
0 |
2013-05-28 |
1,428,954 |
Premium* |
|
Sierra Oncology Inc |
SRRA |
Director, 10% Owner |
2015-07-21 |
0 |
2017-02-14 |
8,112,121 |
Premium* |
|
Anaptysbio Inc |
ANAB |
Director |
2020-11-16 |
80,812 |
2020-11-16 |
199,529 |
Premium* |
|
Alpine Immune Sciences Inc |
ALPN |
|
2022-02-11 |
1,484,115 |
2024-04-25 |
2,829,347 |
Premium* |
|
Allena Pharmaceuticals, Inc. |
ALNA |
Director, 10% Owner |
2017-11-06 |
0 |
2017-11-06 |
3,330,373 |
Premium* |
|
Aptinyx Inc. |
APTX |
Director |
2018-06-25 |
0 |
2020-03-31 |
3,195,055 |
Premium* |
|
Entasis Therapeutics Holdings Inc. |
ETTX |
Director, 10% Owner |
2018-09-28 |
0 |
2018-09-28 |
1,349,953 |
Premium* |
|
Mirum Pharmaceuticals, Inc. |
MIRM |
10% Owner |
2019-07-22 |
3,566,912 |
2019-07-22 |
0 |
Premium* |
|
Arcutis Biotherapeutics, Inc. |
ARQT |
10% Owner |
2020-02-04 |
10,542,790 |
|
0 |
Premium* |
|
Passage Bio, Inc. |
PASG |
10% Owner |
2020-03-03 |
5,009,219 |
2020-03-03 |
0 |
Premium* |
|
Phathom Pharmaceuticals, Inc. |
PHAT |
Director, 10% Owner |
2023-05-25 |
21,596 |
2023-05-25 |
5,831,328 |
Premium* |
|
Newamsterdam Pharma Ord Shs |
NAMS |
|
|
0 |
2024-03-26 |
6,809,429 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
93 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 4
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
LJPC |
La Jolla Pharmaceutical C... |
Director |
|
2009-02-26 |
4 |
S |
$0.06 |
$154,927 |
I/I |
(2,756,711) |
0 |
0 |
- |
|
ANAB |
Anaptysbio Inc |
Director |
|
2018-05-11 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,673,024) |
0 |
0 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2007-06-05 |
4 |
A |
$0.00 |
$0 |
I/I |
2,600,014 |
13,128 |
0 |
- |
|
PHAT |
Phathom Pharmaceuticals, ... |
Director |
|
2023-05-25 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
21,596 |
0 |
- |
|
ANAB |
Anaptysbio Inc |
Director |
|
2018-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
31,854 |
31,854 |
0 |
- |
|
ANAB |
Anaptysbio Inc |
Director |
|
2020-11-16 |
4 |
A |
$0.00 |
$0 |
D/D |
48,958 |
80,812 |
0 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2007-06-27 |
4 |
B |
$11.11 |
$1,043,901 |
I/I |
91,612 |
91,612 |
2.25 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2007-06-27 |
4 |
B |
$10.95 |
$585,463 |
I/I |
52,788 |
144,400 |
2.25 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2007-06-28 |
4 |
B |
$11.32 |
$53,954 |
I/I |
4,734 |
149,134 |
2.25 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2007-06-28 |
4 |
B |
$11.48 |
$49,201 |
I/I |
4,281 |
153,415 |
2.25 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2007-06-29 |
4 |
B |
$11.41 |
$159,538 |
I/I |
13,900 |
167,315 |
2.25 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2007-07-25 |
4 |
B |
$11.35 |
$341,342 |
I/I |
29,700 |
197,015 |
2.25 |
- |
|
ANAB |
Anaptysbio Inc |
Director |
|
2020-11-16 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,416,747) |
199,529 |
0 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2007-07-26 |
4 |
B |
$11.19 |
$44,083 |
I/I |
3,896 |
200,911 |
2.25 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2007-07-26 |
4 |
B |
$11.44 |
$47,160 |
I/I |
4,104 |
205,015 |
2.25 |
- |
|
ANAB |
Anaptysbio Inc |
Director |
|
2017-01-31 |
4 |
A |
$0.00 |
$0 |
I/I |
3,171,212 |
209,095 |
0 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2007-07-27 |
4 |
B |
$11.26 |
$202,951 |
I/I |
17,800 |
222,815 |
2.25 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2007-08-08 |
4 |
B |
$11.50 |
$340,400 |
I/I |
29,600 |
252,415 |
2.25 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2008-01-31 |
4 |
B |
$9.38 |
$60,020 |
I/I |
6,215 |
258,630 |
2.25 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2008-01-31 |
4 |
B |
$9.81 |
$227,815 |
I/I |
22,885 |
281,515 |
2.25 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2008-01-31 |
4 |
B |
$10.21 |
$90,824 |
I/I |
8,800 |
290,315 |
2.25 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2008-02-01 |
4 |
B |
$9.01 |
$50,729 |
I/I |
5,600 |
295,915 |
2.25 |
- |
|
ANAB |
Anaptysbio Inc |
Director |
|
2017-01-31 |
4 |
B |
$15.00 |
$6,000,000 |
I/I |
400,000 |
297,804 |
2.25 |
- |
|
ANAB |
Anaptysbio Inc |
Director |
|
2018-05-11 |
4 |
A |
$0.00 |
$0 |
I/I |
301,024 |
301,024 |
0 |
- |
|
FOLD |
Amicus Therapeutics Inc |
Director |
|
2008-02-01 |
4 |
B |
$9.09 |
$296,107 |
I/I |
32,100 |
328,015 |
2.25 |
- |
|
93 Records found
|
|
Page 1 of 4 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|